Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple negative breast
Search Results
Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple-Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple-negative breast cancer Institutions: University of Tennessee Cancer
Sonia Oskouei, Amy Graham Russell, Yolaine Jeune-Smith, and Ajeet Gajra
critical therapies with the potential to lower cost of care. There are 9 FDA approved therapeutic oncology biosimilars to 3 reference molecules: trastuzumab (5), bevacizumab (2) and rituximab (2), in addition to supportive care biosimilars for hematopoietic
Presented by: Nadeem R. Abu-Rustum
as bevacizumab and pembrolizumab is difficult in this patient population, because bevacizumab and pembrolizumab are not widely available, are expensive, and require specific expertise to be delivered. Despite their improved activity over traditional
Amin Haiderali, Min Huang, Wilbur Pan, Grace Fox, Dylan Maciel, and Andrew Frederickson
nab-paclitaxel for PFS. Statistical superiority was also reported for pembrolizumab+paclitaxel compared to paclitaxel (for OS and PFS), paclitaxel+ bevacizumab (for OS) and ixabepilone+bevacizumab (for OS). Conclusions : These analyses suggest
Leora Horn
guidelines, maintenance therapy is an option for select patients with tumor response or stable disease and is not considered the standard of care for all patients. Category 1 options in continuation maintenance therapy include single-agent bevacizumab and
Bendamustine and Bevacizumab for Patients With Advanced Cancers Principal Investigator: Apostolia M. Tsimberidou, MD, PhD Condition: Advanced cancers Institution: The University of Texas MD Anderson Cancer Center, Houston, Texas Bendamustine is
Presented by: Deborah K. Armstrong
enrolled patients with newly diagnosed, stage III–IV, high-grade serous/endometrioid ovarian, fallopian tube, or primary peritoneal cancer. 2 All subjects had to have undergone ≥3 cycles of bevacizumab with their initial chemotherapy. At the end of
Presented by: Dustin A. Deming
molecular features of the tumor. Across the continuum of treatment, patients usually received FOLFOX (5-FU/leucovorin/oxaliplatin) and/or FOLFIRI (5-FU/leucovorin/irinotecan) ± bevacizumab and an agent targeting the epidermal growth factor receptor (EGFR
NCCN Breast Cancer Panel Reaffirms Current Position and Recommendation Regarding the Use of Bevacizumab in Metastatic Breast Cancer The Expert Breast Cancer Panel of the NCCN met July 10–12, 2011, in Philadelphia, Pennsylvania. The
